A generation ago, the idea that a country could effectively eliminate cervical cancer would have sounded extraordinarily ambitious. Today, Australia is moving closer to making it a public-health reality. The Australian Government says the country is on track to become the first nation in the world to actively eliminate cervical cancer as a public health problem by 2035, following decades of coordinated investment in HPV vaccination, cervical screening, early detection, treatment and public-health infrastructure. The latest national data show how far the country has travelled: Australia’s cervical cancer incidence fell to 6.3 cases per 100,000 women in 2021, and, remarkably, no cervical cancer cases were diagnosed among women under 25 that year, the first time this had occurred since national records began in 1982. Elimination does not mean cervical cancer will completely disappear or that no Australian will ever develop the disease again. Under the internationally recognised public-health benchmark, it means reducing incidence below four cases per 100,000 women annually and sustaining that achievement. Australia’s journey is therefore not a story about discovering a miracle cure. It is something potentially even more consequential: evidence that a cancer responsible for hundreds of thousands of deaths globally can be pushed toward elimination through prevention systems that already exist.
The reason cervical cancer presents such an extraordinary opportunity is that its principal cause is unusually well understood. Almost all cervical cancers are associated with persistent infection by high-risk types of human papillomavirus, or HPV, an extremely common virus transmitted primarily through sexual contact. Most HPV infections clear naturally, but persistent infection with certain high-risk strains can cause abnormal cellular changes in the cervix that may gradually progress to cancer. This process can take many years, creating a valuable window in which healthcare systems can intervene. Vaccination can prevent infection with the HPV types responsible for most cervical cancers, while screening can detect high-risk HPV or precancerous changes before invasive cancer develops. When abnormalities are identified and treated early, progression can often be prevented. Cervical cancer is therefore unusual among major cancers because humanity possesses a powerful combination of primary prevention through vaccination, secondary prevention through screening and effective treatment of precancerous disease. Australia’s achievement has been to deploy these tools systematically across a population rather than relying on any single intervention.
A defining moment came in 2007, when Australia became the first country to introduce a nationally funded HPV vaccination programme, initially targeting girls and young women before expanding vaccination to boys. This was a strategically important decision because HPV transmission occurs across populations, and vaccinating both sexes strengthens community protection while preventing other HPV-related diseases and cancers. Australia also implemented a broad catch-up programme, enabling older adolescents and young adults to benefit rather than limiting protection to a single incoming school cohort. Over time, vaccinated generations began moving into adulthood with substantially lower exposure to the HPV types most strongly associated with cervical cancer. This illustrates one of the most important principles of preventive healthcare: the benefits of decisions made today may take decades to become fully visible, but when prevention works at population scale, it can fundamentally change the future burden of disease.
Vaccination alone, however, cannot eliminate cervical cancer quickly enough because millions of adults were already exposed to HPV before vaccination programmes began, while no vaccination programme reaches every eligible person. Australia’s second major advantage has therefore been its National Cervical Screening Program. Screening has existed nationally since 1991, but the programme underwent a fundamental transformation in 2017 when Australia replaced the traditional Pap test as the primary screening method with a more sensitive HPV-based Cervical Screening Test. Rather than primarily looking for abnormal cells after changes have occurred, the newer approach detects HPV infection associated with the risk of those changes developing. Eligible women and people with a cervix aged 25 to 74 are generally invited to screen every five years. This shift reflects a broader transformation in modern medicine: identifying risk earlier in the disease pathway rather than waiting for visible disease to emerge.
Australia has also expanded access to self-collected HPV testing, an innovation with potentially enormous global significance. Conventional cervical screening can create barriers involving embarrassment, cultural concerns, previous trauma, geography, disability, time, cost or discomfort with clinician-collected samples. Self-collection allows eligible people, under appropriate healthcare arrangements, to collect their own vaginal sample for HPV testing. This can make screening more acceptable to people who might otherwise remain unscreened. The innovation demonstrates that achieving elimination is not simply about possessing excellent medical technology; it requires designing healthcare around the realities of human behaviour. A screening test that exists but is not used cannot prevent cancer. By reducing practical and psychological barriers, self-collection can help reach populations that conventional systems have historically struggled to serve.
Australia’s National Strategy for the Elimination of Cervical Cancer, launched in 2023, brings these interventions into a single national framework with ambitious measurable targets. The strategy extends the global vaccination ambition to 90% coverage among both girls and boys, seeks 70% participation in five-yearly cervical screening among eligible people aged 25 to 74, and raises the treatment target to 95% for people with detected precancer or cervical cancer. The ultimate objective is to reduce incidence below four cases per 100,000 women by 2035 while ensuring elimination is achieved equitably across different population groups. The Australian Government committed AUD 48.2 million over four years when launching the strategy to improve screening access, follow-up services, data and targeted vaccination efforts. This is a critical feature of the Australian model: elimination has been turned from an aspiration into a managed national programme with targets, funding, surveillance and accountability.
The word “elimination” requires careful explanation. Australia is not predicting that cervical cancer cases will fall permanently to zero by 2035. Public-health elimination means reducing the disease to such a low incidence that it is no longer considered a major public-health problem, while continuing interventions to keep it there. For cervical cancer, the benchmark is fewer than four new cases per 100,000 women annually. Modelling cited by the Australian Institute of Health and Welfare projects that Australia could cross this threshold by 2035 and eventually fall below one new case per 100,000 women by around 2066 if prevention and screening gains are sustained. Vaccination and screening would still need to continue after elimination because HPV would not disappear entirely and future generations would remain vulnerable without prevention. In other words, elimination is not the end of the programme; it is the result of maintaining it successfully.
The decline already visible among younger Australians provides some of the strongest evidence that the strategy is working. The absence of diagnosed cervical cancer among women younger than 25 in 2021 is particularly striking because younger generations are increasingly those who benefited from HPV vaccination before significant exposure to the virus. Population-level effects take time to mature, but these trends illustrate how vaccination can progressively reshape the epidemiology of cancer. A programme delivered largely to schoolchildren can eventually reduce cancer incidence decades later. This is preventive medicine operating on a generational timescale.
Australia’s progress also demonstrates why vaccination and screening must work together. Vaccination protects most effectively when administered before exposure to HPV, but it does not eliminate every oncogenic HPV type and cannot retroactively prevent infections acquired before vaccination. Screening therefore remains essential even among vaccinated populations. Conversely, screening without vaccination requires healthcare systems to continually identify and treat large numbers of precancerous lesions created by ongoing viral transmission. Combining both interventions attacks the disease from two directions: vaccination dramatically reduces the number of high-risk infections entering the population, while screening detects the remaining risks before they become invasive cancer. Treatment completes the pathway by ensuring detected abnormalities are actually managed. The success is therefore not attributable to one injection or one test but to an integrated prevention ecosystem.
This distinction is important because the Australian experience offers a broader lesson about how health systems achieve transformative outcomes. Healthcare innovation is frequently associated with spectacular breakthroughs, a new drug, robotic surgery, artificial intelligence or gene therapy. Yet some of the greatest improvements in population health come from combining existing technologies into systems that reliably reach millions of people. HPV vaccines must be purchased, distributed and administered. Screening invitations must reach eligible populations. Laboratories must process tests accurately. Positive results must trigger follow-up. Precancerous lesions must be treated. Cancer patients must reach appropriate specialists. Data systems must identify gaps. Public communication must build trust. A medical technology becomes a public-health breakthrough only when delivery systems make it work at scale.
The economic implications are substantial. Cancer treatment can involve surgery, radiotherapy, chemotherapy, specialist care, hospitalisation and long-term management, while advanced disease can remove people from employment, reduce household income and impose enormous emotional and financial burdens on families. Preventing cancer before it develops changes this economic equation. Vaccination and screening require sustained upfront investment, but successful prevention can avoid decades of treatment expenditure and productivity losses. Cervical cancer prevention therefore demonstrates why governments should sometimes evaluate healthcare spending across generations rather than annual budgets. A vaccine administered to an adolescent today may prevent an expensive and potentially fatal cancer decades later.
The Australian story also illustrates the growing importance of health data. Elimination cannot be declared through optimism; it must be measured. Vaccination registries, screening records, cancer registries, laboratory systems and demographic data allow policymakers to understand who is protected, who is being screened, where disease remains concentrated and which communities are being left behind. This makes cervical cancer elimination increasingly a problem of precision public health. National averages can look impressive while concealing vulnerable populations with substantially worse outcomes. Data must therefore move beyond measuring overall progress toward identifying exactly where prevention systems are failing.
That challenge remains one of Australia’s most important unfinished tasks. National elimination does not automatically mean equitable elimination. Aboriginal and Torres Strait Islander women have historically experienced higher cervical cancer incidence and mortality and can face barriers involving healthcare access, geography, culturally safe services and screening participation. Australia’s own immunisation guidance acknowledges that while modelling suggests the country can achieve elimination, higher incidence and inequalities in screening and treatment may delay elimination among Indigenous women. Rural and remote communities, culturally and linguistically diverse populations, people experiencing socioeconomic disadvantage and those who have historically been underscreened can also require targeted approaches. A country cannot meaningfully celebrate eliminating a preventable cancer nationally while particular communities continue experiencing a disproportionate burden.
This is why Australia’s target of 95% treatment access is particularly significant. Screening without treatment can create the appearance of progress while failing patients after abnormalities are detected. In weaker health systems, women may receive positive screening results but face months of delays, long journeys to specialist facilities, unaffordable procedures or fragmented referral systems. True elimination requires a complete pathway from vaccination to screening, diagnosis, treatment and follow-up. Every broken link reduces the value of the others.
The global context makes Australia’s progress both inspiring and uncomfortable. According to the World Health Organization, approximately 94% of cervical cancer deaths in 2022 occurred in low- and middle-income countries. This extraordinary disparity exists even though the fundamental tools required to prevent most cervical cancers are known. Women are not dying primarily because science has failed to understand the disease. Many are dying because health systems have failed to deliver vaccination, screening, diagnosis and treatment equitably. Cervical cancer has therefore become one of the clearest examples of how inequality determines who benefits from medical progress.
The WHO’s global strategy seeks to eliminate cervical cancer as a public-health problem worldwide through the 90–70–90 targets: 90% of girls fully vaccinated against HPV by age 15, 70% of women screened with a high-performance test by ages 35 and again by 45, and 90% of women identified with cervical disease receiving appropriate treatment. Australia has adapted these ambitions upward in some areas, including vaccination of boys and girls and a 95% treatment target. The broader global message is powerful: unlike many cancers where prevention remains biologically difficult, humanity already possesses a roadmap capable of dramatically reducing cervical cancer. The principal challenge is implementation.
For Africa, the implications could hardly be more important. Cervical cancer remains a major cause of cancer illness and death among women across many African countries, where screening coverage is often limited and cancers are frequently diagnosed at advanced stages. Yet the continent also has structural advantages that could support a different future. Many countries already possess extensive childhood immunisation networks, rapidly expanding digital health systems, widespread mobile-phone access and growing community-health-worker programmes. Integrating HPV vaccination into established school and community platforms while expanding high-performance HPV screening could accelerate prevention dramatically.
Africa does not necessarily need to reproduce Australia’s journey over the same decades. It can leapfrog. Australia began with cytology-based Pap screening and later transitioned to primary HPV testing. Countries building or expanding programmes today can move directly toward more sensitive HPV-based approaches where feasible. Self-collection could be especially transformative in rural areas where specialist clinicians are scarce. Samples could be collected closer to communities, transported through integrated laboratory networks and tracked digitally. Mobile platforms could send screening reminders, communicate results and coordinate referrals. Telemedicine could connect regional clinicians with specialists. Digital payment and health-financing systems could reduce out-of-pocket barriers. Artificial intelligence may eventually support diagnostic triage. The combination of vaccination, self-sampling, digital health and decentralised care could allow countries with fewer resources to build programmes designed for modern realities rather than copying historical models.
Uganda and other African countries also have an opportunity to frame cervical cancer elimination as more than a Ministry of Health programme. It requires collaboration across education, finance, technology, local government, civil society and the private sector. Schools are essential for adolescent vaccination. Community organisations can build trust and counter misinformation. Telecom networks can support reminders and health communication. Digital identity and health records can improve continuity. Financial institutions and insurers can reduce catastrophic treatment costs. Employers can promote screening. Religious and cultural leaders can help address misconceptions. Elimination is fundamentally an ecosystem challenge.
There is also a powerful gender and economic inclusion dimension. Women are often central to household wellbeing, caregiving, agriculture, informal trade and small enterprise. When cervical cancer causes disability or premature death, the consequences extend beyond the individual patient to children, household income and community productivity. Preventing cervical cancer therefore contributes not only to women’s health but to economic resilience. Investments in HPV vaccination and screening should be understood as investments in human capital.
Australia is now extending its experience beyond its borders. Through regional cervical cancer elimination partnerships, the Australian Government and partners are supporting efforts across the Indo-Pacific, recognising that becoming the first country to achieve elimination would be far less meaningful if neighbouring countries continued experiencing preventable deaths at high rates. At the 2025 Global Cervical Cancer Elimination Forum, Australia announced an additional AUD 5.5 million for the Elimination Partnership in the Indo-Pacific for Cervical Cancer, taking the Australian Government contribution to AUD 22 million; combined with funding from the Minderoo Foundation, the partnership total reached AUD 35.1 million. This represents an important evolution from national success toward global health diplomacy and technology transfer.
Australia’s progress ultimately challenges one of the most persistent assumptions about cancer: that humanity must simply accept cancer as an unavoidable consequence of biology and aging. Some cancers remain extraordinarily difficult to prevent, but cervical cancer is different. Its primary viral cause is known. Highly effective vaccines exist. Sensitive screening technologies exist. Precancerous disease can be detected and treated. The pathway to elimination is therefore not theoretical.
The viral claim that Australia could become the first nation to eliminate cervical cancer is substantially grounded in current evidence, provided the word “eliminate” is understood correctly. Australia has not eliminated cervical cancer yet, nor does the 2035 target mean cases will fall to absolute zero. But the Australian Government, national monitoring data and international health authorities support the conclusion that the country is on track to become the first to reduce cervical cancer below the internationally recognised elimination threshold through active public-health intervention.
What makes the achievement potentially historic is not simply that one wealthy country may cross a statistical threshold. It is what that threshold would prove to the rest of the world. Cervical cancer could become one of the first major human cancers pushed toward elimination through coordinated vaccination, screening and treatment.
If Australia succeeds, the question facing the world will change. It will no longer be whether cervical cancer can be eliminated. It will be why any woman, anywhere, should continue dying from a cancer humanity already knows how to prevent.
